Sinovac COVID-19 approved for emergency use among children aged 3 to 17 in China

Chinese firm Sinovac's vaccine versus COVID-19 has been approved for emergency use among individuals aged 3 to 17 years old in China.

In a statement, Sinovac said Coronavac had been used among childrenin China since its emergency use approval on May 28.

According to Sinovac, the results of its phase II clinical study on 180 volunteers within the age group showed that three months after two doses of the vaccine, seroconversion rates for low doses group and medium doses group were 98.9% and 100%, respectively.

"The geometric mean titer (GMT) of neutralizing antibody was close to the level recorded at 28 days after vaccination and remained significantly higher than the level recorded in adults and elderly at 28 days after vaccination," Sinovac said.

"This indicates that CoronaVac has stable and good immunogenicity among the children and adolescent population, recording better results compared to those in people aged 18 and above," it added.

Sinovac said CoronaVac was also approved for use in individuals aged 12 to 17 years old in Indonesia in June. —NB, GMA News